New Perspectives Inc’s AbbVie ABBV Stock Holding History

New Perspectives Inc’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$262K	Hold	1,041	–	–	0.08%	42
2026 Q1	$226K	Buy	1,041 +4	+0.4%	+$887	0.08%	42
2025 Q4	$237K	Buy	1,037 +4	+0.4%	+$911	0.08%	41
2025 Q3	$239K	Buy	+1,033	New	+$210K	0.11%	37
2025 Q2	–	Sell	-1,024	Closed	-$215K	–	37
2025 Q1	$215K	Buy	+1,024	New	+$199K	0.11%	36
2024 Q4	–	Sell	-1,015	Closed	-$200K	–	36
2024 Q3	$200K	Buy	+1,015	New	+$189K	0.11%	37

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

New Perspectives Inc's ABBV Position: Q2 2026 in Review

New Perspectives Inc held its AbbVie (ABBV) position steady in Q2 2026 at 1,041 shares worth $262K. The position accounts for 0.08% of the portfolio, ranked #42.

New Perspectives Inc first reported a position in ABBV in Q3 2024 and has held it in 6 quarters since. 4,188 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

New Perspectives Inc held 1,041 shares of AbbVie worth $262K as of Q2 2026.
New Perspectives Inc left its AbbVie share count unchanged in Q2 2026.
AbbVie made up 0.08% of New Perspectives Inc's portfolio in Q2 2026, its #42 holding.
New Perspectives Inc first reported a position in AbbVie in Q3 2024 and has held it in 6 quarters since.
4,188 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on New Perspectives Inc's 13F filing for Q2 2026, filed 22 Jul 2026.